NCT01747239终止2 期
Cabazitaxel in Platinum Refractory Ovarian Cancer. A Phase II Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 4
- 主要终点
- Rate of response to cabazitaxel
研究概览
简要总结
Ovarian cancer patients are considered platinum refractory if their disease worsens during primary platinum treatment or if they have no effect of the treatment. This constitutes a major therapeutic problem and new treatment approaches are highly needed.
Cabazitaxel (Jevtana®) is a new taxane with effect in breast and prostatic cancer. In both tumors it has effect in patients refractory to taxotere. Consequently, it could be anticipated that cabazitaxel may have an effect in platinum refractory ovarian cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer. Stages I-IV.
- •Patients with refractory disease defined as progression or no change during primary treatment, as evaluated after 3 and/or 6 cycles of platinum/paclitaxel. Prior to inclusion, patients must have received platinum and paclitaxel as combination treatment.
- •Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or evaluable by Gynecologic Cancer Interest Group (GCIG) cancer antigen 125 (CA-125) criteria.
- •Age ≥ 18 years.
- •Performance stage 0-
- •Adequate bone marrow function, liver function, renal function, and coagulation parameters (within 7 days prior to inclusion):
- •Neutrophils (ANC) ≥ 1.5 x 10^9/l
- •Platelet count ≥ 100 x 10^9/l
- •Serum bilirubin ≤ 1.0 x upper limit of normal (ULN)
- •Serum transaminase ≤ 2.5 x ULN
- •Serum creatinine ≤ 1.5 ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI)and patients with creatinine clearance <60 mL/min should be excluded
- •Written informed consent.
排除标准
- •History of severe hypersensitivity reaction (≥grade 3) to taxol.
- •History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs.
- •Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P4503A4/5 (a one week wash-out period is necessary for patients who are already on these treatments).
- •Neuropathy grade ≥
- •Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at screening is mandatory.
- •Fertile patients not willing to use effective methods of contraception during treatment and for 6 months after the end of treatment.
- •Other malignant diseases within 5 years prior to inclusion in the study, except basal cell or squamous cell carcinoma of the skin and cervical carcinoma-in-situ.
- •Other experimental therapy or participation in another clinical trial within 28 days prior to treatment initiation.
- •History of any chronic medical or psychiatric condition or laboratory abnormality that is not medically controlled or in the opinion of the investigator may increase the risks associated with study drug administration. (e.g. diabetes, cardiac diseases, hypertension, renal, thyroid or liver disease).
- •Vaccination with yellow fever vaccine or any live attenuated vaccine during the treatment.
- •Treatment with disulfiram (antabuse)
研究组 & 干预措施
Cabazitaxel
Experimental
25 mg/m2 IV every three weeks
干预措施: Cabazitaxel (Drug)
结局指标
主要结局
Rate of response to cabazitaxel
时间窗: Every 9 weeks up to two years
Response must be confirmed by a second CT scan 4-6 weeks after first response by CT scan
次要结局
- Progression free survival(Every three months until progression or death, up to three years)
- Overall survival(Every 3 months up to three years)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
Cabazitaxel in ovarian cancer patients who do not respond to platinum-based chemotherapy. A phase II trialEUCTR2012-001224-35-DKVejle Hospital
已完成
2 期
Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.Ovarian CancerNCT02560337Vejle Hospital26
已完成
2 期
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorPlatinum Refractory Epithelial Ovarian CancerPrimary Cancer of the PeritoneumCancer of the Fallopian TubeNCT00543049AGO Study Group73
进行中（未招募）
不适用
Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyPlatinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)EUCTR2007-003089-16-DEAGO Research GmbH72
终止
2 期
Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian CancerOvarian NeoplasmsNCT00919984Korea Cancer Center Hospital22